If the decision is allowed to stand, it will have major implications for pharmaceutical patents and biomedical innovation.
Your institute does not have access to this article
Open Access articles citing this article.
Naunyn-Schmiedeberg's Archives of Pharmacology Open Access 14 January 2021
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Du, M.M. United States District Court. District of Nevada. Case 2:16-cv-02525-MMD-NJK. Document 381 (30 March 2020).
Bays, H. E. et al. Am. J. Cardiol. 108, 682–690 (2011).
Bhatt, D. L. et al. N. Engl. J. Med. 380, 11–22 (2019).
Ford, R. A. Cornell Law Rev. 99, 71–128 (2013).
Mori, T. A. et al. Am. J. Clin. Nutr. 71, 1085–1094 (2000).
Thryv, Inc. v. Click-To-Call Technologies, LP, 590 US (2020).
Mason, R. P., Libby, P. & Bhatt, D. L. Arterioscler. Thromb. Vasc. Biol. 40, 1135–1147 (2020).
D.L.B. was the chair and international principal investigator of REDUCE-IT, with funding paid to Brigham and Women’s Hospital, and discloses the following relationships: advisory board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Level Ex, Medscape Cardiology, PhaseBio, PLx Pharma, Regado Biosciences; board of directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; chair: American Heart Association Quality Oversight Committee; data monitoring committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; honoraria: American College of Cardiology (senior associate editor, clinical trials and news, ACC.org; vice-chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; clinical trial steering committee for RE-DUAL PCI, funded by Boehringer Ingelheim; executive committee for AEGIS-II, funded by CSL Behring), Belvoir Publications (editor in chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (editor in chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), Medtelligence/ReachMD (CME steering committees), Level Ex, MJH Life Sciences, Population Health Research Institute (operations committee, publications committee, steering committee and USA national co-leader for COMPASS, funded by Bayer), Slack Publications (chief medical editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), WebMD (CME steering committees); other: Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), VA CART Research and Publications Committee (chair); research funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; royalties: Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); site co-investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; trustee: American College of Cardiology; unfunded research: FlowCo, Merck, Novo Nordisk, Takeda.
About this article
Cite this article
Curfman, G., Bhatt, D.L. & Pencina, M. Federal judge invalidates icosapent ethyl patents — but on the basis of a common statistical mistake. Nat Biotechnol 38, 939–941 (2020). https://doi.org/10.1038/s41587-020-0616-y
Naunyn-Schmiedeberg's Archives of Pharmacology (2021)